A Phase 2 interventional study of Reduced intensity conditioning and Rapid immunosuppressive taper in Multiple Myeloma, Lymphocytic Leukemia, Chronic and Lymphoma, Low-Grade, sponsored by University of Michigan Rogel Cancer Center. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2017-03-08.
Sponsored by University of Michigan Rogel Cancer Center · Phase 2, Interventional, and Treatment
The purpose of this study is to determine whether a reduced intensity conditioning regimen for stem cell transplant with donor cells will allow the donor cells to be effective without causing health problems.
In this research study patients will receive dosages of chemotherapy that are lower than the usual dosages. The study will determine whether a shorter duration of immunosuppression will permit the donor cells to be effective against the cancer without causing more severe GVHD (Graft Versus Host Disease). Also to be determined is whether the patient's cancer can be prevented from relapsing after blood stem cell transplant by using prophylactic treatment, giving a donor leukocyte infusion BEFORE a relapse happens.
In this research study samples of blood and bone marrow will be analyzed. These samples will be examined to study the cellular production of inflammatory cytokine levels in attempt to be able to predict which patients will have complications like GVHD or relapse.
3,632 studies on the registry are indexed under Multiple Myeloma; 745 are open to participants now.
This study's enrollment of 54 is above the median of 41 across 2,907 interventional studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →University of Michigan Rogel Cancer Center is the lead sponsor of 316 studies on the registry; 46 are open to participants now.
Of its 46 completed or terminated interventional studies of FDA-regulated products, 30 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patient Inclusion Criteria:
To be eligible a patient MUST meet at least one of the next 4 criteria
Any patient, regardless of age, with one of the following hematological malignancies:
Multiple myeloma
To be eligible a patient MUST meet all of the following criteria
In addition to the above criteria ALL patients must meet the following minimum organ function:
Patient Exclusion Criteria:
Donor Inclusion Criteria:
Donor Exclusion Criteria:
Reduced intensity conditioning consisting of Busulfan and Fludarabine(fludarabine 150 mg/m2 IV, busulfan 6 mg/kg IV, total lymphoid irradiation 2 Gy), followed by a rapid immunosuppressive taper of Tacrolimus (0.06 mg/kg q12h, PO, Days -7 to +28), Methotrexate (5 mg/m2, IV, Days +1, +3, +6, +11) and Mycophenolate Mofetil (10 mg/kg every 8 hours, PO, Days -6 to +7).
Procedure: Reduced intensity conditioning · Procedure: Rapid immunosuppressive taper · Procedure: Prophylactic donor leukocyte infusions
Busulfan and Fludarabine regimen
Taper of Tacrolimus, Methotrexate and Mycophenolate Mofetil
If the patient has GVHD overall grade 0-1 or skin grade 1 on day +100, then 5 x 107 CD3+ cells/kg recipient weight are given.
Percentage of Participants With Acute Graft Versus Host Disease (GVHD) Grades 2-4
The primary objective of this study was to establish the rate of acute GVHD following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies. Glucksberg staging was used for organ grading of GVHD. Clinical GVHD was assessed as follows: Grade 0: No stage 1-4 of any organ Grade 1: Stage 1-2 rash and no liver or gut involvement Grade 2: Stage 3 rash, or Stage 1 liver involvement, or Stage 1 GI Grade 3: Stage 0-3 skin with Stage 2-3 liver, or Stage 2-4 GI Grade 4: Stage 4 skin rash, or Stage 4 liver involvement
Time frame: 100 days
Percentage of Participants With Progression Free Survival
The second primary objective was to determine the percentage of participants with progression free survival following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies. We define disease progression as disease recurrence within 180 days of transplant.
Time frame: two years
Percentage of Patients Alive at 2 Years
To estimate the overall survival of patients progression following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies.
Time frame: 2 Years
| Milestone | Immunosuppression Taper |
|---|---|
| Started | 54 |
| Completed | 54 |
| Not completed | 0 |
The primary objective of this study was to establish the rate of acute GVHD following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies. Glucksberg staging was used for organ grading of GVHD. Clinical GVHD was assessed as follows: Grade 0: No stage 1-4 of any organ Grade 1: Stage 1-2 rash and no liver or gut involvement Grade 2: Stage 3 rash, or Stage 1 liver involvement, or Stage 1 GI Grade 3: Stage 0-3 skin with Stage 2-3 liver, or Stage 2-4 GI Grade 4: Stage 4 skin rash, or Stage 4 liver involvement
| percentage of participants | Immunosuppression Taper |
|---|---|
| Percentage of Participants With Acute Graft Versus Host Disease (GVHD) Grades 2-4 | 73 |
The second primary objective was to determine the percentage of participants with progression free survival following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies. We define disease progression as disease recurrence within 180 days of transplant.
| percentage of participants | Immunosuppression Taper |
|---|---|
| Percentage of Participants With Progression Free Survival | 35 |
To estimate the overall survival of patients progression following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies.
| percentage of participants | Immunosuppression Taper |
|---|---|
| Percentage of Patients Alive at 2 Years | 38 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Immunosuppression Taper | — | 42/54 (77.8%) | 30/54 (55.6%) |
| Event | Immunosuppression Taper |
|---|---|
| InfectionInfections and infestations | 16/54 |
| DiarrheaGastrointestinal disorders | 10/54 |
| GVHDImmune system disorders | 9/54 |
| FeverGeneral disorders | 5/54 |
| VomitingGastrointestinal disorders | 4/54 |
| NauseaGastrointestinal disorders | 4/54 |
| Abdominal painGastrointestinal disorders | 4/54 |
| DeathGeneral disorders | 3/54 |
| HypotensionCardiac disorders | 2/54 |
| PyrexiaGeneral disorders | 2/54 |
| Event | Immunosuppression Taper |
|---|---|
| HyperglycemiaMetabolism and nutrition disorders | 29/54 |
| HypocalcemiaMetabolism and nutrition disorders | 28/54 |
| HypoalbuminemiaMetabolism and nutrition disorders | 24/54 |
| HypomagnesemiaMetabolism and nutrition disorders | 23/54 |
| HyponatremiaMetabolism and nutrition disorders | 20/54 |
| ASTInvestigations | 20/54 |
| ALTInvestigations | 20/54 |
| CreatinineInvestigations | 18/54 |
| HypokalemiaMetabolism and nutrition disorders | 17/54 |
| HypermagnesemiaMetabolism and nutrition disorders | 16/54 |
54 patients were enrolled however 9 patients did not receive planned donor lymphocyte infusion. 45 patients were analyzed.
| Age, Continuous(years) | Immunosuppression Taper |
|---|---|
| Median | 56 (2 to 67) |
| Gender(Participants) | Immunosuppression Taper |
|---|---|
| Female | 22 |
| Male | 23 |
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Michigan Rogel Cancer Center